2:02 PM
 | 
May 16, 2018
 |  BC Extra  |  Clinical News

Nektar reports updated response data for immuno-oncology combo

Nektar Therapeutics (NASDAQ:NKTR) reported response data from 60 evaluable patients with solid tumors who were naïve to immunotherapy in the Phase Ib/II PIVOT-02 trial evaluating the company's NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab. The data were released in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

NKTR-214 is an immunostimulatory cytokine engineered to selectively activate IL-2 receptor beta chain (CD122; IL2RB) receptors on cytotoxic T cells, resulting in increased PD-1...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >